Systems and a device for a pathogen detection system are described herein. For example, a pathogen detection system may include a pathogen detection device comprising an inlet, an outlet, and a reactive chamber; an imaging system comprising an excitation source and a fluorescence detection system; a substrate; and a heating element. In some examples, the pathogen detection system may be configured to detect one or more pathogens and/or viruses in a sample. For example, the pathogen detection device may receive a solution containing at least one of DNA or RNA and route the solution to the reactive chamber. Upon heating the solution, the pathogen detection device may further receive a probe containing one or more fluorescent dyes. The excitation source may excite the solution, and the detection system may detect an emission of the one or more fluorescent dyes.

A method for nucleic acid isolation comprising: receiving a binding moiety solution within a process chamber; mixing the binding moiety solution with a biological sample, within the process chamber, in order to produce a moiety-sample mixture; incubating the moiety-sample mixture during a time window, thereby producing a solution comprising a set of moiety-bound nucleic acid particles and a waste volume; separating the set of moiety-bound nucleic acid particles from the waste volume; washing the set of moiety-bound nucleic acid particles; and releasing a nucleic acid sample from the set of moiety-bound nucleic acid particles. The method preferably utilizes a binding moiety comprising at least one of poly(allylamine) and polypropylenimine tetramine dendrimer, both of which reversibly bind and unbind to nucleic acids based upon environmental pH.

The present invention provides a reagent and method for detecting a replication-competent lentivirus (RCL) by fluorescence quantitative real-time polymerase chain reaction (PCR). In particular, the present invention provides a primer and probe combination for detecting RCL, and a method for performing detection using said primer and probe; the present invention also provides a reagent kit comprising said primer and probe. The primer and probe combination of the present invention detects RCL with high amplification efficiency and good specificity, and can be used for RCL detection and RCL monitoring of clinical patient peripheral blood samples which may occur during a production process.

The present invention provides a reagent and method for detecting a replication-competent lentivirus (RCL) by fluorescence quantitative real-time polymerase chain reaction (PCR). In particular, the present invention provides a primer and probe combination for detecting RCL, and a method for performing detection using said primer and probe; the present invention also provides a reagent kit comprising said primer and probe. The primer and probe combination of the present invention detects RCL with high amplification efficiency and good specificity, and can be used for RCL detection and RCL monitoring of clinical patient peripheral blood samples which may occur during a production process.

The present invention relates to a diagnostic assay for the virus causing severe acute respiratory syndrome Sars-CoV 2 (COVID-19, COVID-19; COVID-19-CoV-2) in humans (“COVID-19 virus”). In particular, the invention relates to a real-time quantitative PCR assay for the detection of COVID-19 virus using reverse transcription and polymerase chain reaction. Specifically, the qualitative assay is a TaqMan® assay using the primers and probes constructed based on the genome of the COVID-19 virus. The invention further relates to a diagnostic kit that comprises nucleic acid molecules for the detection of the COVID-19 virus.

The present invention relates to assays, including amplification assays, conducted in the presence of modulators. These assays can be used to detect the presence of particular nucleic acid sequences. In particular, these assays can allow for genotyping or other genetic analysis.

The present invention relates to assays, including amplification assays, conducted in the presence of modulators. These assays can be used to detect the presence of particular nucleic acid sequences. In particular, these assays can allow for genotyping or other genetic analysis.

The present invention relates to a method for identifying a compound that prevents, ameliorates and/or inhibits a hepatitis virus (HBV) infection, wherein a compound that reduces the expression and/or activity of PAP associated domain containing 5 (PAPD5) and/or PAP associated domain containing 7 (PAPD7) is identified as a compound that prevents, ameliorates and/or inhibits a BV infection. The invention also provides for inhibitors of PAPD5 or PAPD7 for use in treating and/or preventing a HBV infection; as well as a combined preparation comprising an inhibitor of PAPD5 and an inhibitor of PAPD7 for simultaneous or sequential use in the treatment or prevention of a HBV infection. Also comprised in the present invention is a pharmaceutical composition for use in the treatment and/or prevention of a HBV infection, and a method for monitoring the therapeutic success during the treatment of a HBV infection.

Disclosed herein are methods for molecularly characterizing cervical cell samples as being negative for intraepithelial lesion or malignancy (NILM), low-grade squamous intraepithelial lesion (LSIL), or high-grade squamous intraepithelial lesion (HSIL).

A portable diagnostic device for performing the diagnosis of pathogens, such as viruses, bacteria, microorganisms, etc., by rapidly detecting their nucleic acids in a biological sample to be tested. Also, the use of the portable diagnostic device and the methods for detection of at least one nucleic acid sequence of interest implemented with the aid of the portable diagnostic device.